Literature DB >> 17101197

Isoform-specific effects of ApoE on HSV immediate early gene expression and establishment of latency.

R M Miller1, H J Federoff.   

Abstract

Alzheimer's disease (AD) is a common and devastating neurodegenerative disease in which most cases are of unknown, sporadic origin. In addition to age, the most prevalent known risk factor for developing AD is carriage of the epsilon4 allele of Apolipoprotein E (ApoE). Carriage of the epsilon2 or epsilon3 allele of ApoE confers protection or no change in risk for AD, respectively. Latent herpes simplex virus type 1 (HSV-1) infection in the brain concurrent with ApoE4 carriage exacerbates risk for AD, suggesting that these two factors interact to promote neuronal dysfunction and degeneration in selective brain areas. Indeed, HSV-1 DNA has been found in regions primarily affected by AD, such as the temporal lobes, hippocampus, and neocortex. We hypothesize that HSV-1 infection in the background of ApoE4, but not ApoE2 or ApoE3, promotes an environment more conducive to neuronal degeneration. To investigate this idea, we have utilized transgenic mice that express human ApoE2, 3, or 4 alleles from astrocytes in a murine ApoE -/- background. We find that carriage of the different ApoE alleles dramatically affects HSV-1 immediate early gene expression as well as the establishment of latency. Both of these factors are poised to impact neuronal viability, inflammation, and viral spread. Our data support the concept that HSV-1 and ApoE4 interact to provide an environment conducive to the development and/or spread of AD.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17101197     DOI: 10.1016/j.neurobiolaging.2006.09.006

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN: 0197-4580            Impact factor:   4.673


  9 in total

1.  Antiviral agents in Alzheimer's disease: hope for the future?

Authors:  Matthew A Wozniak; Ruth F Itzhaki
Journal:  Ther Adv Neurol Disord       Date:  2010-05       Impact factor: 6.570

Review 2.  Viral and inflammatory triggers of neurodegenerative diseases.

Authors:  Michela Deleidi; Ole Isacson
Journal:  Sci Transl Med       Date:  2012-02-15       Impact factor: 17.956

3.  APOE genotype is associated with oral herpetic lesions but not genital or oral herpes simplex virus shedding.

Authors:  David M Koelle; Amalia Magaret; Terri Warren; Gerard D Schellenberg; Anna Wald
Journal:  Sex Transm Infect       Date:  2010-04-21       Impact factor: 3.519

4.  Effect of human apolipoprotein E genotype on the pathogenesis of experimental ocular HSV-1.

Authors:  Partha S Bhattacharjee; Donna M Neumann; Timothy P Foster; Saadallah Bouhanik; Christian Clement; Dass Vinay; Hilary W Thompson; James M Hill
Journal:  Exp Eye Res       Date:  2008-05-18       Impact factor: 3.467

5.  Human APOE isoform-dependent effects on brain beta-amyloid levels in PDAPP transgenic mice.

Authors:  Kelly R Bales; Feng Liu; Su Wu; Suizhen Lin; Deanna Koger; Cynthia DeLong; Jeffrey C Hansen; Patrick M Sullivan; Steven M Paul
Journal:  J Neurosci       Date:  2009-05-27       Impact factor: 6.167

6.  Herpes simplex virus type 1 and Alzheimer's disease: the autophagy connection.

Authors:  Ruth F Itzhaki; S Louise Cosby; Matthew A Wozniak
Journal:  J Neurovirol       Date:  2008-01       Impact factor: 2.643

Review 7.  Corroboration of a Major Role for Herpes Simplex Virus Type 1 in Alzheimer's Disease.

Authors:  Ruth F Itzhaki
Journal:  Front Aging Neurosci       Date:  2018-10-19       Impact factor: 5.750

Review 8.  Apolipoprotein E in Cardiometabolic and Neurological Health and Diseases.

Authors:  Jeyashree Alagarsamy; Anja Jaeschke; David Y Hui
Journal:  Int J Mol Sci       Date:  2022-08-31       Impact factor: 6.208

Review 9.  Contributions of neurotropic human herpesviruses herpes simplex virus 1 and human herpesvirus 6 to neurodegenerative disease pathology.

Authors:  Jessica M Hogestyn; David J Mock; Margot Mayer-Proschel
Journal:  Neural Regen Res       Date:  2018-02       Impact factor: 5.135

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.